High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths

Bone Marrow Transplantation

Volumn 23, Issue 11, 1999, Pages 1123-1129

  Baker, K S ^a,d   Roncarolo, M G ^c   Peters, C ^a   Bigler, M ^b   DeFor, T ^a   Blazar, B R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone marrow transplant; GVHD; Interleukin 10; Transplant related complications

Indexed keywords

ANTIBODY; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MORTALITY; MULTIPLE ORGAN FAILURE; PNEUMONIA; PRIORITY JOURNAL; VEIN OCCLUSION;

EID: 0033048626     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701780     Document Type: Article

References (37)

1. Champlin RE, Gale RP. The early complications of bone marrow transplantation. Semin Hematol 1984; 21: 101-108.
2. Bortin MM, Horowitz MM, Gale RP. Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry. Nat Immun Cell Growth Regul 1988; 7: 334-350.
3. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
4. Jones RJ, Lee KS, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
5. Krowka MJ, Rosenow EC, Hoagland HC. Pulmonary complications of bone marrow transplantation. Chest 1985; 87: 237-246.
6. Weiner RS, Horowitz MM, Gale RP et al. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. Br J Haematol 1989; 71: 535-543.
7. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
8. Nestel FP, Price KS, Seemayer TA et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-113.
9. Piguet PF, Grau GE, Allet B et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987; 166: 1280-1289.
10. McCarthy PL Jr, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
11. Baker KS, Allen RD, Roths JB et al. Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease. Bone Marrow Transplant 1995; 15: 595-603.
12. Panoskaltsis-Mortari A, Taylor PA, Yaeger TM et al. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J Clin Invest 1997; 100: 1015-1027.
13. Hsu DH, de Waal Malefyt R, Fiorentino DF et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250: 830-832.
14. Vieira P, de Waal Malefyt R, Dang MN et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991; 88: 1172-1176.
15. Fiorentino DF, Zlotnik A, Vieira P et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
16. Howard M, O'Garra A, Ishida H et al. Biological properties of interleukin 10. J Clin Immunol 1992; 12: 239-247.
17. + T cell clones and peripheral blood T cells. J Immunol 1992; 149: 2378-2384.
18. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigenpresenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
19. de Waal Malefyt R, Abrams J, Bennett B et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
20. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754-4765.
21. Ralph P, Nakoinz I, Sampson-Johannes A et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148: 808-814.
22. Takanaski S, Nonaka R, Xing Z et al. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 1994; 180: 711-715.
23. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med 1984; 35: 11-24.
24. Weisdorf DJ, Snover DC, Haake R et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629.
25. Wagner JE, Santos GW, Noga SJ et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990; 75: 1370-1377.
26. Huhn RD, Radwanski E, O'Connell SM et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699-705.
27. + T cell mediated graft-versus-host disease. Transplantation 1998; 66: 1220-1229.
28. Hempel L, Korholz D, Nussbaum P et al. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 365-368.
29. Cavet J, Middleton PG, Davies SM et al. Linkage of cytokine gene polymorphisms to early death and acute graft-versus-host disease severity in HLA-identical sibling transplants. Blood 1998; 92: 685a (Abstr. 2821).
30. Holler E, Ertl B, Hintermeier-Knabe R et al. Inflammatory reactions induced by pretransplant conditioning - an alternative target for modulation of acute GVHD and complications following allogeneic bone marrow transplantation? Leuk Lymphoma 1997; 25: 217-224.
31. + T cells. J Immunol 1998; 160: 3188-3193.
32. Gorczynski RM, Wojcik D. A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-I, and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion. J Immunol 1994; 152: 2011-2019.
33. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281-1294.
34. Hancock W, Mottram PL, Purcell LJ et al. Prolonged survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is associated with selective intragraft cytokine protein expression: interleukin (IL)-4 and IL-10 but not IL-2 or interferon-gamma. Transplant Proc 1993; 25: 2937-2938.
35. Abramowicz D, Durez P, Gerard C et al. Neonatal induction of transplantation tolerance in mice is associated with in vivo expression of IL-4 and -10 mRNAs. Transplant Proc 1993; 25: 312-313.
36. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA-mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493-502.
37. Bacchetta R, Parkman R, McMahon M et al. Dysfunctional cytokine production by host-reactive T-cell clones isolated from a chimeric severe combined immunodeficiency patient transplanted with haploidentical bone marrow. Blood 1995; 85: 1944-1953.